A significant improvement in lung function and annual asthma exacerbation rate was noted vs placebo.
Patients with obesity who are hospitalized for an acute exacerbation of COPD may have longer hospital stays and more often require mechanical ventilation.
Prenatal tobacco smoke exposure appears to be associated with airflow obstruction in children who have asthma.
Patients treated with dupilumab experienced fewer asthma exacerbations than the overall population.
Mobile devices may help patients with asthma better manage and control their disease.
Pediatric patients benefited from orally administered injectable dexamethasone for asthma exacerbations.
A survey that was part of the Severe Asthma Research Program found a specific subgroup of patients with asthma who have highly variable asthma control.
Montelukast therapy reduced the need for rescue medication in young children with recurring wheezing illness.
Investigators evaluated respiratory viruses, atypical bacteria, and atopy on the severity of asthma and the effect on recovery.
The modifying effect of human rhinovirus on asthma exacerbation severity was examined in a pediatric population.
In children with cystic fibrosis, risk for first detection of S aureus and P aeruginosa was greater in those who had received antibiotic prophylaxis.
Patients with asthma were found to have higher blood eosinophil counts, fractional exhaled nitric oxide levels, and total serum IgE concentrations compared with patients with COPD.
Salmeterol plus fluticasone was associated with a significant increase in sputum bacterial load in chronic obstructive pulmonary disease, compared to salmeterol alone.
Rheumatoid arthritis increased the risk of COPD-related hospitalization by 47%.
Although some pregnant women discontinue their asthma medications for fear of fetal drug toxicity, they may be putting their babies at greater risk.
Researchers assessed the efficacy of a once-daily treatment option for controlled asthma.
In a retrospective analysis, researchers examined the efficacy of beta blocker therapy in prolonging patients' lives.
A 3-variable score that encompasses dyspnea score, prednisone use, and prior hospitalization for COPD exacerbations can predict mortality and readmission risk.
A recent study examined whether nebulized glycopyrrolate is safe to use in patients with severe COPD and comorbid cardiovascular risk factors.
The safety of concurrently administering nebulized glycopyrrolate with long-acting beta agonists was examined in 3 studies.